BLUF:
Healthpeak Properties (NYSE:DOC) holds a BBB+ credit rating from S&P and Baa1 from Moody’s, both with stable outlooks, and maintains an approximately 28% dividend buffer, with full-year 2025 AFFO of approximately $1.69 per share against an annualized dividend of $1.22. The monthly payout structure is stable and the balance sheet remains solidly investment grade. The variable worth watching is the post-separation earnings structure — Janus Living’s IPO closed March 23, 2026, removing 34 senior housing assets from the consolidated entity, and management has not yet provided post-separation AFFO guidance. The dividend is not under pressure today. The coverage is now estimated, not directly observable.

The Stability Case

Healthpeak enters the post-separation period from a position of relative balance sheet strength. Net Debt to Adjusted EBITDAre stood at 5.2x at year-end 2025, within investment-grade norms for diversified healthcare REITs, and liquidity reached approximately $2.4 billion. The BBB+ and Baa1 ratings reflect that credit agencies view the leverage profile as manageable given the asset quality and tenant mix across outpatient medical and life science segments.

The dividend itself has been consistent. The $1.22 annualized payout — distributed monthly at $0.10167 per share — has been maintained without reduction through the merger integration with Physicians Realty Trust and through the Janus Living separation process. Full-year 2025 AFFO of approximately $1.69 per share implies coverage of roughly 1.38x, a buffer that is meaningful but not expansive by Healthcare REIT standards. That coverage, however, was generated under the pre-separation structure.

Management’s 2026 FFO as Adjusted guidance of $1.70 to $1.74 per share signals that the core operating segments — outpatient medical and life science — are expected to generate stable to modestly growing earnings. Same-store cash NOI growth of 3.9% in the fourth quarter of 2025 supports that trajectory. The outpatient medical portfolio recorded 88% lease retention for the full year, and life science lease executions showed positive releasing spreads. These are the operating metrics that anchor the stability case.

Where Caution Is Warranted

The Janus Living separation introduces a structural variable that the current coverage ratio does not fully resolve. The $1.69 AFFO figure reflects the consolidated entity — including senior housing operations that have now been contributed to Janus Living. The post-separation DOC is a different earnings structure than the one that generated that figure.

This is not a coverage problem. It is a measurement problem. The earnings base has changed. The coverage framework has not yet caught up.

Management has indicated it will receive approximately $10 million annually in management fees from Janus Living, and that its pro rata share of regular Janus Living distributions is expected to help maintain the $1.22 dividend. But neither a revised AFFO per share figure for the stripped-down entity nor a post-separation payout ratio has been formally disclosed. The 2026 FFO guidance of $1.70 to $1.74 per share was issued in early February, before the IPO priced and closed in late March.

That gap — between pre-separation guidance and post-separation reality — is where the structural question sits. The $840 million Janus Living IPO was upsized, which is a constructive signal for capital allocation. But until Healthpeak reports its first full quarter as a standalone outpatient medical and life science REIT, the 28% buffer figure carries an asterisk. The coverage is estimated, not confirmed, against the new earnings base.

What Would Shift The Narrative

The first is post-separation AFFO disclosure. When Healthpeak reports Q1 2026 results — the first observable data point for the post-separation structure — the market will have its initial read on whether the $1.70 to $1.74 FFO guidance range holds. If AFFO per share prints below $1.60, coverage compresses toward approximately 1.30x on a re-based structure. If it tracks toward $1.65 or above, the stability case strengthens considerably.

The second is capital deployment outcome from Janus Living proceeds. Management indicated IPO proceeds would be directed toward debt repayment and growth capital recycling, including a $1 billion disposition and recapitalization program targeting higher-growth outpatient medical and life science assets. If leverage drifts above 5.5x during the transition — rather than compressing toward 5.0x as implied — the credit cushion supporting the BBB+ rating begins to thin.

What I’d Watch

The first is Q1 2026 AFFO per share relative to the $1.22 dividend. This is the first observable data point for the re-based earnings structure. A coverage ratio that holds at or above 1.30x confirms the post-separation structure. A print below 1.20x changes the conversation.

The second is Net Debt to Adjusted EBITDAre at mid-year 2026. The separation was designed in part to reduce balance sheet complexity. If leverage does not compress from the 5.2x year-end 2025 level as capital is redeployed into Gateway Crossing and life science acquisitions, the buffer between investment-grade and stress territory narrows.

Post-separation, Healthpeak is a more focused company — outpatient medical and life science assets, with a management relationship to a separately traded senior housing REIT. The 28% buffer and BBB+ rating reflect the prior consolidated structure. Whether those figures hold through the first full quarter of reported results as a standalone entity is the variable that determines whether the current stability case survives. Or whether the coverage ratio must be recalibrated against a structurally smaller earnings base.

SourceLine: AFFO and dividend figures based on company filings and management guidance. Credit ratings reflect most recent agency publications. Janus Living IPO details sourced from company press releases. All figures in USD. This is not investment advice.

Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.